FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

76 letters match. Newest first.

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium
  3. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  4. NativeMed LLC dba NativeMed

    FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  5. HydraMed IV LLC dba HydraMed

    FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  6. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low
  7. FitRX, LLC dba AM RX

    FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  8. Altru Telehealth, LLC dba Altru Telehealth

    FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.

    Low
  9. Eden Health International Inc. dba Eden

    FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  10. Trinity HealthCare Supply, LLC dba altRx

    FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.

    Low
  11. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  12. Thrivelab Co. dba Thrivelab

    FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

    Medium
  13. VivioMD Group LLC dba VivioMD

    FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.

    Low
  14. Glow Medispa, LLC dba Mint Med

    FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.

    Low
  15. Nexlife Inc. dba Nexlife

    FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.

    Low
  16. Public Health Solution LLC dba DrMedHealth

    FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.

    Low
  17. D&H Medical Services

    FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.

    Low
  18. Momentum Health 360 dba Momentum Health

    FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.

    Low
  19. Medica Weight Loss

    FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.

    Medium
  20. Ezra Holdco LLC dba Ezra

    FDA says Ezra's website misbrands compounded semaglutide and tirzepatide by labeling them as Ezra-made when they are not.

    Low
  21. Ready Med

    FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.

    Low
  22. FITISH

    FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.

    Low
  23. OrderlyMeds LLC dba OrderlyMeds

    FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.

    Low
  24. Roen Health, Inc. dba RoenRx

    FDA warned RoenRx that its website misbrands compounded semaglutide with misleading approval claims and a company label implying it makes the drug.

    Medium
  25. Joi and Blokes dba Joi + Blokes

    FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.

    Medium
  26. Nova Vascular LLC dba NOVARX

    FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.

    Low
  27. Clover Meds LLC dba Clover Meds

    Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.

    Medium
  28. Maximus Health, Inc. dba Maximus

    FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.

    Low
  29. ImmunityBio, Inc.

    FDA says ImmunityBio's Anktiva TV ad and podcast falsely claim it can cure or prevent all cancers.

    High risk
  30. Premium Health Management Inc. dba Premium Health

    FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  31. Zeuss LLC dba Zeuss

    FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.

    Medium
  32. Lean Rx, Inc. dba SkinnyRx

    SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.

    Low
  33. Kare Solutions, LLC dba Zappy

    FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.

    Low
  34. Strut Health, LLC dba Strut

    FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.

    Low
  35. Refills Health, LLC dba Refills Health

    FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.

    Medium
  36. Weightless Medical LLC dba WeightCare

    FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.

    Low
  37. Viv Health, Inc. dba VIV RX

    FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  38. Peaks Curative, LLC dba Peaks

    FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.

    Low
  39. PharmaZee

    FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.

    Low
  40. Good Girl LLC dba GoodGirlRX

    FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.

    Medium
  41. Ivim Services LLC dba Ivim

    FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.

    Low
  42. Join Josie

    FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.

    Low
  43. Kin Meds

    FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.

    Low
  44. Levity Inc. dba Levity

    FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.

    Low
  45. MaxLife Technologies Inc. dba Maxlife

    FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.

    Medium
  46. Better Health Labs, Inc. dba Measured

    FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.

    Medium
  47. MEDVi, LLC dba MEDVi

    FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.

    Medium
  48. Newman Clinic, PLLC dba Newman Clinic

    FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  49. NewSelf Limited dba NewSelf

    FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.

    Low
  50. 24HrDoc, Inc. dba 24HrDoc

    FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.

    Medium